|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
lactacystin inhibits the reaction [AGT protein results in increased degradation of SYP protein] |
CTD |
PMID:18487452 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects localization |
ISO EXP |
lactacystin inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein] lactacystin inhibits the reaction [geldanamycin results in increased degradation of AHR protein]; lactacystin inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein] lactacystin affects the localization of AHR protein |
CTD |
PMID:10722677 PMID:12237327 PMID:17445780 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization affects localization multiple interactions |
ISO |
lactacystin results in increased localization of AIFM1 protein lactacystin affects the localization of AIFM1 protein ATRN protein affects the reaction [lactacystin affects the localization of AIFM1 protein]; U 0126 inhibits the reaction [lactacystin results in increased localization of AIFM1 protein] |
CTD |
PMID:16860906 PMID:21683092 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Apob |
apolipoprotein B |
multiple interactions increases secretion increases expression |
ISO |
acetylleucyl-leucyl-norleucinal inhibits the reaction [lactacystin results in decreased expression of and results in decreased secretion of APOB protein]; HSPA5 promotes the reaction [lactacystin results in increased expression of APOB protein]; HSPA5 promotes the reaction [lactacystin results in increased secretion of APOB protein]; lactacystin inhibits the reaction [HSPA5 results in increased degradation of APOB protein]; lactacystin results in increased expression of and results in increased secretion of APOB protein |
CTD |
PMID:15618547 PMID:19383982 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
lactacystin inhibits the reaction [resveratrol results in decreased secretion of APP protein] |
CTD |
PMID:16162502 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
lactacystin inhibits the reaction [Cadmium Chloride results in decreased expression of ATP1A1 protein] |
CTD |
PMID:10506578 |
|
NCBI chr 2:204,003,742...204,032,023
Ensembl chr 2:204,003,742...204,032,023
|
|
G |
Atrn |
attractin |
multiple interactions decreases response to substance |
ISO |
ATRN protein affects the reaction [lactacystin affects the localization of AIFM1 protein] ATRN protein results in decreased susceptibility to lactacystin |
CTD |
PMID:16860906 |
|
NCBI chr 3:123,434,409...123,567,922
Ensembl chr 3:123,434,409...123,567,918
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
EXP ISO |
lactacystin results in decreased expression of BCL2 protein lactacystin inhibits the reaction [sodium bichromate results in decreased expression of BCL2 protein] lactacystin inhibits the reaction [[pirinixic acid results in increased expression of UCP2 protein] which results in increased degradation of BCL2 protein]; Sirolimus inhibits the reaction [lactacystin results in decreased expression of BCL2 protein] |
CTD |
PMID:18544562 PMID:18640276 PMID:19361538 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15673306 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression multiple interactions |
EXP ISO |
lactacystin results in increased activity of CASP3 protein lactacystin results in increased expression of CASP3 protein modified form [lactacystin results in increased activity of CASP3 protein] which results in increased cleavage of SPTAN1 protein; calpeptin inhibits the reaction [[lactacystin results in increased activity of CASP3 protein] which results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:15618349 PMID:20649845 PMID:21683092 PMID:29944914 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 protein]] |
CTD |
PMID:20671745 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Curcumin results in increased degradation of CCND1 protein] |
CTD |
PMID:18156803 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Curcumin results in increased degradation of CCNE1 protein] |
CTD |
PMID:18156803 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO EXP |
lactacystin inhibits the reaction [[cobaltiprotoporphyrin binds to HPX protein] which results in increased degradation of CCS protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] lactacystin inhibits the reaction [[Copper Sulfate co-treated with 2,3,2-tetramine] results in increased degradation of CCS protein] |
CTD |
PMID:12832419 PMID:19039664 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
lactacystin results in increased expression of CDKN1B protein lactacystin inhibits the reaction [Estradiol results in increased degradation of CDKN1B protein] |
CTD |
PMID:12149143 PMID:17283133 PMID:23029392 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
lactacystin results in increased expression of CEBPB protein |
CTD |
PMID:11779194 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
lactacystin results in increased expression of CEBPD protein |
CTD |
PMID:11779194 |
|
NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
lactacystin inhibits the reaction [TNF protein results in increased expression of COMT protein] |
CTD |
PMID:17138778 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cp |
ceruloplasmin |
decreases degradation |
ISO |
lactacystin results in decreased degradation of CP protein |
CTD |
PMID:16405854 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Indomethacin results in decreased expression of CTNNB1 protein]; lactacystin inhibits the reaction [resveratrol results in increased degradation of CTNNB1 protein] |
CTD |
PMID:11756231 PMID:26040106 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
lactacystin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:10722677 PMID:10777561 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
lactacystin promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:24792400 |
|
NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; lactacystin inhibits the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:24224465 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
lactacystin inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 protein] |
CTD |
PMID:17083955 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; lactacystin inhibits the reaction [Phenobarbital results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:24224465 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
lactacystin results in increased expression of DDIT3 mRNA |
CTD |
PMID:19135031 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; lactacystin inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; lactacystin results in increased expression of and results in increased activity of DIO2 protein |
CTD |
PMID:11425850 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Cadmium Chloride results in decreased expression of EIF4E protein] |
CTD |
PMID:15878868 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Dronabinol results in decreased expression of ERBB2 protein] |
CTD |
PMID:30733293 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Fzr1 |
fizzy and cell division cycle 20 related 1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Estradiol affects the localization of FZR1 protein] |
CTD |
PMID:23029392 |
|
NCBI chr 7:11,201,690...11,213,614
Ensembl chr 7:11,201,690...11,213,613
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [LAMB1 protein affects the localization of GJA1 protein] |
CTD |
PMID:22150760 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
lactacystin inhibits the reaction [diphenylarsinic acid results in increased degradation of GLS protein alternative form] |
CTD |
PMID:22493432 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
increases localization |
EXP |
lactacystin results in increased localization of GRIA1 protein |
CTD |
PMID:19674091 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
increases localization |
EXP |
lactacystin results in increased localization of GRIA2 protein |
CTD |
PMID:19674091 |
|
NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
ISO |
lactacystin results in increased expression of GSTA2 mRNA |
CTD |
PMID:12446695 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
lactacystin inhibits the reaction [geldanamycin results in increased degradation of HIF1A protein] |
CTD |
PMID:11980636 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
lactacystin promotes the reaction [manganese chloride promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]]; lactacystin promotes the reaction [manganese chloride results in increased expression of HMOX1 protein] lactacystin results in increased expression of HMOX1 mRNA |
CTD |
PMID:12441344 PMID:21384399 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpx |
hemopexin |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[cobaltiprotoporphyrin binds to HPX protein] which results in increased degradation of CCS protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:170,423,558...170,431,066
Ensembl chr 1:170,423,483...170,431,073
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
lactacystin results in increased activity of HSF1 protein |
CTD |
PMID:11893605 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hsf2 |
heat shock transcription factor 2 |
increases activity |
ISO |
lactacystin results in increased activity of HSF2 protein |
CTD |
PMID:11893605 |
|
NCBI chr20:38,935,820...38,963,444
Ensembl chr20:38,935,820...38,963,309
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
HSPA5 promotes the reaction [lactacystin results in increased expression of APOB protein]; HSPA5 promotes the reaction [lactacystin results in increased secretion of APOB protein]; lactacystin inhibits the reaction [HSPA5 results in increased degradation of APOB protein] |
CTD |
PMID:15618547 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA] lactacystin inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; lactacystin promotes the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein] |
CTD |
PMID:22398747 PMID:25766886 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
lactacystin inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; lactacystin promotes the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein] |
CTD |
PMID:25766886 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
lactacystin results in increased expression of IL6 mRNA; lactacystin results in increased expression of IL6 protein Quercetin inhibits the reaction [lactacystin results in increased expression of IL6 mRNA]; Quercetin inhibits the reaction [lactacystin results in increased expression of IL6 protein] |
CTD |
PMID:11893605 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
lactacystin promotes the reaction [Tretinoin results in increased expression of ITGAM protein] |
CTD |
PMID:20945414 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [LAMB1 protein affects the localization of GJA1 protein] |
CTD |
PMID:22150760 |
|
NCBI chr 6:50,528,796...50,596,593
Ensembl chr 6:50,528,823...50,596,079
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases activity multiple interactions |
ISO |
lactacystin results in increased activity of MAPK1 protein U 0126 inhibits the reaction [lactacystin results in increased activity of MAPK1 protein] |
CTD |
PMID:21683092 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity multiple interactions |
ISO |
lactacystin results in increased activity of MAPK3 protein U 0126 inhibits the reaction [lactacystin results in increased activity of MAPK3 protein] |
CTD |
PMID:21683092 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases activity increases phosphorylation |
ISO EXP |
lactacystin results in increased activity of MAPK8 protein lactacystin results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:15618349 PMID:18463101 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk8ip1 |
mitogen-activated protein kinase 8 interacting protein 1 |
increases expression |
ISO EXP |
lactacystin results in increased expression of MAPK8IP1 protein |
CTD |
PMID:15618349 |
|
NCBI chr 3:81,295,023...81,304,181
Ensembl chr 3:81,295,024...81,304,181
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases ubiquitination |
ISO |
lactacystin results in increased ubiquitination of MTTP protein |
CTD |
PMID:17405876 |
|
NCBI chr 2:243,366,181...243,407,608
Ensembl chr 2:243,366,181...243,407,608
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression decreases degradation multiple interactions |
ISO EXP |
lactacystin results in increased expression of NFE2L2 protein lactacystin results in decreased degradation of NFE2L2 protein lactacystin promotes the reaction [Cadmium Chloride results in increased expression of NFE2L2 protein] lactacystin promotes the reaction [manganese chloride affects the localization of and results in increased activity of NFE2L2 protein]; lactacystin promotes the reaction [manganese chloride promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]] |
CTD |
PMID:12441344 PMID:12446695 PMID:15322212 PMID:21384399 PMID:26598004 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
lactacystin promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:17644113 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nol3 |
nucleolar protein 3 |
multiple interactions |
EXP |
lactacystin affects the reaction [Doxorubicin results in increased degradation of NOL3 protein] |
CTD |
PMID:19139834 |
|
NCBI chr19:37,232,567...37,236,668
Ensembl chr19:37,235,001...37,236,649
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [GW 7647 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [pirinixic acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]] lactacystin inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [deoxynivalenol results in increased degradation of NOS2 protein]; lactacystin promotes the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein] |
CTD |
PMID:17891158 PMID:19376148 PMID:25766886 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases activity multiple interactions |
ISO |
lactacystin results in decreased activity of NR1I3 protein lactacystin inhibits the reaction [Phenobarbital affects the localization of NR1I3 protein] |
CTD |
PMID:24224465 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Optn |
optineurin |
increases expression multiple interactions |
EXP ISO |
lactacystin results in increased expression of OPTN protein lactacystin results in increased expression of and results in increased ubiquitination of OPTN protein |
CTD |
PMID:21059646 |
|
NCBI chr17:77,167,700...77,218,374
Ensembl chr17:77,167,740...77,218,389
|
|
G |
Otc |
ornithine transcarbamylase |
multiple interactions decreases metabolic processing |
ISO |
lactacystin inhibits the reaction [Oxygen results in decreased metabolism of OTC protein] lactacystin results in decreased metabolism of OTC protein |
CTD |
PMID:11161710 |
|
NCBI chr X:13,524,804...13,601,074
Ensembl chr X:13,524,607...13,601,069
|
|
G |
Park7 |
Parkinsonism associated deglycase |
decreases response to substance |
ISO |
PARK7 protein results in decreased susceptibility to lactacystin |
CTD |
PMID:18331584 |
|
NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
|
|
G |
Pdia2 |
protein disulfide isomerase family A, member 2 |
increases expression |
ISO |
lactacystin results in increased expression of PDIA2 mRNA; lactacystin results in increased expression of PDIA2 protein |
CTD |
PMID:15353226 |
|
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
increases expression |
EXP |
lactacystin results in increased expression of PFKFB3 protein |
CTD |
PMID:19448625 |
|
NCBI chr17:70,632,778...70,713,736
Ensembl chr17:70,684,134...70,713,726
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
lactacystin results in increased expression of PPP1R15A mRNA |
CTD |
PMID:19135031 |
|
NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein] |
CTD |
PMID:17644113 |
|
NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
|
|
G |
Psmb10 |
proteasome 20S subunit beta 10 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to lactacystin |
CTD |
PMID:22398747 |
|
NCBI chr19:37,909,543...37,912,027
Ensembl chr19:37,909,546...37,912,027
|
|
G |
Psmb8 |
proteasome 20S subunit beta 8 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to lactacystin |
CTD |
PMID:22398747 |
|
NCBI chr20:3,990,809...3,993,772
Ensembl chr20:3,990,613...3,993,769
|
|
G |
Psmd4 |
proteasome 26S subunit, non-ATPase 4 |
multiple interactions |
ISO |
lactacystin promotes the reaction [VCP protein binds to UBXN1 protein binds to PSMD4 protein] |
CTD |
PMID:15362974 |
|
NCBI chr 2:196,198,303...196,207,569
Ensembl chr 2:196,198,038...196,207,560
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
increases expression |
ISO |
lactacystin results in increased expression of RBPJ protein |
CTD |
PMID:22302987 |
|
NCBI chr14:59,657,738...59,865,427
Ensembl chr14:59,658,935...59,735,450
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein] |
CTD |
PMID:17644113 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [tin protoporphyrin IX inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]] |
CTD |
PMID:18344023 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
multiple interactions decreases expression |
ISO |
lactacystin inhibits the reaction [Estradiol results in increased expression of SKP2 protein] lactacystin results in decreased expression of SKP2 protein |
CTD |
PMID:23029392 |
|
NCBI chr 2:58,506,146...58,534,211
Ensembl chr 2:58,506,151...58,534,211
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [resveratrol results in decreased expression of SLC10A2 protein] |
CTD |
PMID:24498857 |
|
NCBI chr16:90,324,420...90,350,254
Ensembl chr16:90,324,361...90,345,865
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [Cisplatin results in increased degradation of SLC31A1 protein] |
CTD |
PMID:17108132 |
|
NCBI chr 5:78,222,504...78,249,358
Ensembl chr 5:78,222,504...78,249,358
|
|
G |
Slc38a3 |
solute carrier family 38, member 3 |
multiple interactions |
EXP |
lactacystin inhibits the reaction [manganese chloride results in increased degradation of SLC38A3 protein] |
CTD |
PMID:20737472 |
|
NCBI chr 8:116,406,258...116,423,752
Ensembl chr 8:116,406,241...116,422,366
|
|
G |
Snca |
synuclein alpha |
multiple interactions decreases expression |
ISO EXP |
lactacystin promotes the reaction [SNCA protein mutant form binds to SNCA protein mutant form] lactacystin results in decreased expression of SNCA protein |
CTD |
PMID:16584840 PMID:18818210 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions affects localization |
ISO |
lactacystin inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein] lactacystin affects the localization of SOD1 protein mutant form Copper promotes the reaction [lactacystin affects the localization of SOD1 protein mutant form]; Ditiocarb inhibits the reaction [lactacystin affects the localization of SOD1 protein mutant form] |
CTD |
PMID:15034941 PMID:17309078 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
multiple interactions increases cleavage |
ISO |
[lactacystin results in increased activity of CASP3 protein] which results in increased cleavage of SPTAN1 protein; calpain inhibitor III inhibits the reaction [lactacystin results in increased cleavage of SPTAN1 protein]; calpeptin inhibits the reaction [[lactacystin results in increased activity of CASP3 protein] which results in increased cleavage of SPTAN1 protein]; calpeptin inhibits the reaction [lactacystin results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:21683092 |
|
NCBI chr 3:8,534,437...8,599,259
Ensembl chr 3:8,534,440...8,599,260
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[Cisplatin results in increased phosphorylation of TP63 protein alternative form] which results in increased degradation of STK11 protein] |
CTD |
PMID:21191146 |
|
NCBI chr 7:12,440,751...12,457,513
Ensembl chr 7:12,440,751...12,457,513
|
|
G |
Syp |
synaptophysin |
multiple interactions |
EXP |
lactacystin inhibits the reaction [AGT protein results in increased degradation of SYP protein] |
CTD |
PMID:18487452 |
|
NCBI chr X:15,694,699...15,709,244
Ensembl chr X:15,695,566...15,707,436
|
|
G |
Tbx21 |
T-box transcription factor 21 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr10:85,032,799...85,049,331
Ensembl chr10:85,032,799...85,049,331
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [tin protoporphyrin IX inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]] |
CTD |
PMID:18344023 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
multiple interactions |
ISO |
lactacystin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA] |
CTD |
PMID:12147270 |
|
NCBI chr 2:157,316,293...157,342,979
Ensembl chr 2:157,316,266...157,341,469
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
lactacystin inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [TNF protein results in increased expression of COMT protein]; lactacystin promotes the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein] lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA]; lactacystin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:17138778 PMID:18809656 PMID:22398747 PMID:25766886 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
affects localization |
ISO |
lactacystin affects the localization of TOMM20 protein |
CTD |
PMID:11161710 |
|
NCBI chr19:59,863,421...59,873,411
Ensembl chr19:59,863,421...59,873,411
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases ubiquitination |
EXP |
lactacystin inhibits the reaction [Acetaminophen results in increased degradation of TP53 protein]; lactacystin results in increased phosphorylation of and results in increased expression of TP53 protein lactacystin results in increased ubiquitination of TP53 protein |
CTD |
PMID:16330492 PMID:18463101 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tp63 |
tumor protein p63 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[Cisplatin results in increased phosphorylation of TP63 protein alternative form] which results in increased degradation of STK11 protein]; lactacystin inhibits the reaction [[Cisplatin results in increased phosphorylation of TP63 protein alternative form] which results in increased degradation of TP63 protein alternative form] |
CTD |
PMID:21191146 |
|
NCBI chr11:78,234,853...78,456,559
Ensembl chr11:78,234,800...78,456,501
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
multiple interactions |
ISO |
lactacystin inhibits the reaction [[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 protein]] |
CTD |
PMID:20671745 |
|
NCBI chr X:111,884,285...111,944,693
Ensembl chr X:111,884,295...111,887,906
|
|
G |
Ubxn1 |
UBX domain protein 1 |
multiple interactions |
ISO |
lactacystin promotes the reaction [VCP protein binds to UBXN1 protein binds to PSMD4 protein] |
CTD |
PMID:15362974 |
|
NCBI chr 1:225,067,953...225,071,944
Ensembl chr 1:225,068,009...225,071,945
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
lactacystin inhibits the reaction [[pirinixic acid results in increased expression of UCP2 protein] which results in increased degradation of BCL2 protein] |
CTD |
PMID:19361538 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Vcp |
valosin-containing protein |
multiple interactions increases expression |
ISO |
lactacystin promotes the reaction [VCP protein binds to UBXN1 protein binds to PSMD4 protein] lactacystin results in increased expression of VCP protein |
CTD |
PMID:15362974 |
|
NCBI chr 5:58,426,548...58,445,953
Ensembl chr 5:58,426,549...58,445,953
|
|
G |
Vdr |
vitamin D receptor |
decreases degradation |
ISO |
lactacystin results in decreased degradation of VDR protein |
CTD |
PMID:24792400 |
|
NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases response to substance |
ISO |
XBP1 protein results in decreased susceptibility to lactacystin |
CTD |
PMID:19135031 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene E4 |
CTD |
PMID:8621850 PMID:10764316 PMID:12794006 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
affects binding multiple interactions |
ISO |
Leukotriene E4 binds to CYSLTR1 protein [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein; montelukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] Leukotriene E4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein] |
CTD |
PMID:8384568 PMID:9620942 PMID:10462554 PMID:11705452 PMID:12853847 |
|
NCBI chr X:77,671,028...77,700,491
Ensembl chr X:77,674,150...77,700,269
|
|
G |
Cysltr2 |
cysteinyl leukotriene receptor 2 |
multiple interactions increases activity |
ISO |
[Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene E4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein |
CTD |
PMID:10851239 PMID:11093801 |
|
NCBI chr15:54,903,290...54,941,742
Ensembl chr15:54,905,274...54,906,203
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Leukotriene E4 results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:24,733,306...24,739,194
Ensembl chr18:24,734,330...24,735,349
|
|
G |
Il13 |
interleukin 13 |
increases abundance |
EXP |
IL13 protein results in increased abundance of Leukotriene E4 |
CTD |
PMID:12654629 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Leukotriene E4 results in decreased activity of MGST1 protein |
CTD |
PMID:9890956 |
|
NCBI chr 4:172,119,382...172,134,609
Ensembl chr 4:172,119,331...172,134,607
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
increases expression |
EXP |
Leukotriene E4 results in increased expression of MUC5AC protein |
CTD |
PMID:12654629 |
|
NCBI chr 1:214,725,482...214,756,653
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased abundance of Leukotriene E4] |
CTD |
PMID:25432964 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of APAF1 protein |
CTD |
PMID:15967204 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of BAX protein |
CTD |
PMID:15967204 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of BCL2 protein |
CTD |
PMID:15967204 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
alpha-Tocopherol inhibits the reaction [S-(1,2-dichlorovinyl)cysteine results in increased activity of CASP3 protein] |
CTD |
PMID:29129777 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased activity of CASP7 protein alpha-Tocopherol inhibits the reaction [S-(1,2-dichlorovinyl)cysteine results in increased activity of CASP7 protein] |
CTD |
PMID:29129777 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased activity of CASP8 protein |
CTD |
PMID:29129777 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases cleavage increases activity |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased cleavage of CASP9 protein S-(1,2-dichlorovinyl)cysteine results in increased activity of CASP9 protein |
CTD |
PMID:15967204 PMID:29129777 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of CCND1 protein |
CTD |
PMID:16495211 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of CDK4 protein |
CTD |
PMID:16495211 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of CDK6 protein |
CTD |
PMID:16495211 |
|
NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in decreased expression of CDKN2A protein |
CTD |
PMID:16495211 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
multiple interactions decreases activity |
EXP |
Aminooxyacetic Acid inhibits the reaction [S-(1,2-dichlorovinyl)cysteine results in decreased activity of DLD protein] |
CTD |
PMID:2360207 |
|
NCBI chr 6:50,597,677...50,618,694
Ensembl chr 6:50,597,677...50,618,694
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
EXP |
S-(1,2-dichlorovinyl)cysteine results in decreased activity of GSR protein |
CTD |
PMID:2360207 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of JUN protein |
CTD |
PMID:15967204 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased cleavage of PARP1 protein |
CTD |
PMID:15967204 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
increases phosphorylation decreases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased phosphorylation of PPP1CA protein S-(1,2-dichlorovinyl)cysteine results in decreased expression of PPP1CA protein |
CTD |
PMID:16495211 |
|
NCBI chr 1:219,439,953...219,443,570
Ensembl chr 1:219,439,953...219,443,570
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased phosphorylation of RB1 protein |
CTD |
PMID:16495211 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of RELA protein |
CTD |
PMID:15967204 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Slc25a10 |
solute carrier family 25 member 10 |
multiple interactions |
EXP |
[SLC25A10 protein co-treated with Glutathione] results in decreased susceptibility to S-(1,2-dichlorovinyl)cysteine |
CTD |
PMID:12388626 |
|
NCBI chr10:109,665,682...109,674,782
Ensembl chr10:109,665,682...109,673,143
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine results in increased expression of TP53 protein |
CTD |
PMID:15967204 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Vim |
vimentin |
increases expression |
EXP |
S-(1,2-dichlorovinyl)cysteine results in increased expression of VIM mRNA |
CTD |
PMID:10996665 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases phosphorylation |
ISO |
dorsomorphin inhibits the reaction [S-allylcysteine results in increased phosphorylation of ACACA protein]; S-allylcysteine promotes the reaction [Fatty Acids, Nonesterified results in increased phosphorylation of ACACA protein]; sirtinol inhibits the reaction [S-allylcysteine results in increased phosphorylation of ACACA protein]; STO 609 inhibits the reaction [S-allylcysteine results in increased phosphorylation of ACACA protein] |
CTD |
PMID:23465592 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
[S-allylcysteine co-treated with lycopene] inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in increased expression of BCL2 protein]; S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in increased expression of BCL2 protein] S-allylcysteine results in decreased expression of BCL2 protein |
CTD |
PMID:16030430 PMID:17155983 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein] |
CTD |
PMID:16030430 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
increases phosphorylation |
ISO |
S-allylcysteine results in increased phosphorylation of CAMK2A protein |
CTD |
PMID:23465592 |
|
NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein] |
CTD |
PMID:32453893 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO EXP |
S-allylcysteine results in increased cleavage of CASP3 protein [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [lead acetate results in increased activity of CASP3 protein] [S-allylcysteine co-treated with lycopene] inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of CASP3 protein] |
CTD |
PMID:16030430 PMID:17155983 PMID:22033380 PMID:32453893 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
EXP ISO |
[S-allylcysteine co-treated with lycopene] inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of CASP8 protein]; S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of CASP8 protein] S-allylcysteine results in increased activity of CASP8 protein [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of CASP8 protein]; S-allylcysteine inhibits the reaction [Diethylnitrosamine results in decreased activity of CASP8 protein]; S-allylcysteine inhibits the reaction [lead acetate results in increased activity of CASP8 protein] |
CTD |
PMID:16030430 PMID:22033380 PMID:31067004 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
S-allylcysteine inhibits the reaction [Cyclosporine results in decreased activity of CAT protein]; S-allylcysteine inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein]; S-allylcysteine inhibits the reaction [Streptozocin results in decreased expression of CAT protein] [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in decreased activity of CAT protein]; S-allylcysteine inhibits the reaction [lead acetate results in decreased activity of CAT protein] |
CTD |
PMID:18548744 PMID:19391111 PMID:20951120 PMID:22033380 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
S-allylcysteine results in increased expression of CDH1 protein |
CTD |
PMID:17155983 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Isoproterenol results in increased expression of CTSD mRNA] |
CTD |
PMID:17182065 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
EXP |
S-allylcysteine results in increased expression of CYP3A2 protein |
CTD |
PMID:16000231 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Fadd |
Fas associated via death domain |
increases expression multiple interactions |
ISO |
S-allylcysteine results in increased expression of FADD protein S-allylcysteine promotes the reaction [FAS protein binds to FADD protein]; SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FADD protein]] |
CTD |
PMID:31067004 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate affects the localization of and results in increased activity of FAS protein]; S-allylcysteine inhibits the reaction [Diethylnitrosamine inhibits the reaction [FAS protein binds to FAS protein]]; S-allylcysteine inhibits the reaction [lead acetate affects the localization of and results in increased activity of FAS protein] S-allylcysteine promotes the reaction [FAS protein binds to FADD protein]; S-allylcysteine promotes the reaction [FAS protein binds to FAS protein]; S-allylcysteine promotes the reaction [FAS protein binds to FASLG protein]; SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FADD protein]]; SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FASLG protein]] |
CTD |
PMID:22033380 PMID:31067004 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
S-allylcysteine promotes the reaction [FAS protein binds to FASLG protein]; SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FASLG protein]] S-allylcysteine results in increased expression of FASLG protein |
CTD |
PMID:31067004 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [Fatty Acids, Nonesterified results in increased expression of FASN mRNA] |
CTD |
PMID:23465592 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Isoproterenol results in increased expression of GAL mRNA] |
CTD |
PMID:17182065 |
|
NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased expression of GOT1 protein] |
CTD |
PMID:22033380 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased expression of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein] S-allylcysteine inhibits the reaction [Cyclosporine results in increased activity of GPT protein] |
CTD |
PMID:19391111 PMID:22033380 PMID:32453893 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Cyclosporine results in decreased activity of GSR protein]; S-allylcysteine inhibits the reaction [Isoproterenol results in decreased activity of GSR protein] |
CTD |
PMID:16757080 PMID:19391111 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Isoproterenol results in increased expression of GUSB mRNA] |
CTD |
PMID:17182065 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein] |
CTD |
PMID:32453893 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein] |
CTD |
PMID:32453893 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jup |
junction plakoglobin |
increases expression |
ISO |
S-allylcysteine results in increased expression of JUP protein |
CTD |
PMID:17155983 |
|
NCBI chr10:88,280,517...88,307,451
Ensembl chr10:88,279,632...88,307,412
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of KCNN4 protein]; S-allylcysteine inhibits the reaction [lead acetate results in increased activity of KCNN4 protein] |
CTD |
PMID:22033380 |
|
NCBI chr 1:81,227,855...81,245,986
Ensembl chr 1:81,230,612...81,245,996
|
|
G |
Klk1 |
kallikrein 1 |
decreases expression |
ISO |
S-allylcysteine results in decreased expression of KLK3 protein |
CTD |
PMID:17155983 |
|
NCBI chr 1:100,131,562...100,135,556
Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Cyclosporine results in increased expression of MMP2 protein] |
CTD |
PMID:19391111 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein] |
CTD |
PMID:32453893 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
EXP |
S-allylcysteine promotes the reaction [Potassium Dichromate results in increased expression of NFE2L2 protein] |
CTD |
PMID:18548744 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein] |
CTD |
PMID:32453893 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2]; S-allylcysteine inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein] |
CTD |
PMID:16614485 PMID:19391111 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Isoproterenol results in decreased expression of OGDH mRNA] |
CTD |
PMID:17182065 |
|
NCBI chr14:86,414,924...86,481,903
Ensembl chr14:86,414,949...86,613,327
|
|
G |
Prdx2 |
peroxiredoxin 2 |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate affects the localization of PRDX2 protein]; [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate promotes the reaction [PRDX2 protein binds to PRDX2 protein]]; S-allylcysteine inhibits the reaction [lead acetate affects the localization of PRDX2 protein]; S-allylcysteine inhibits the reaction [lead acetate promotes the reaction [PRDX2 protein binds to PRDX2 protein]] |
CTD |
PMID:22033380 |
|
NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein] |
CTD |
PMID:32453893 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Cyclosporine results in increased expression of RELA protein] |
CTD |
PMID:19391111 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of SMPD1 protein]; S-allylcysteine inhibits the reaction [lead acetate results in increased activity of SMPD1 protein] |
CTD |
PMID:22033380 |
|
NCBI chr 1:170,383,682...170,387,525
Ensembl chr 1:170,383,682...170,387,524
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
dorsomorphin inhibits the reaction [S-allylcysteine results in decreased expression of SREBF1 protein]; S-allylcysteine inhibits the reaction [Fatty Acids, Nonesterified results in increased expression of and affects the localization of SREBF1 protein]; S-allylcysteine inhibits the reaction [Fatty Acids, Nonesterified results in increased expression of SREBF1 mRNA]; sirtinol inhibits the reaction [S-allylcysteine results in decreased expression of SREBF1 protein]; STO 609 inhibits the reaction [S-allylcysteine results in decreased expression of SREBF1 protein] |
CTD |
PMID:23465592 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
S-allylcysteine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] |
CTD |
PMID:16614485 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein] |
CTD |
PMID:32453893 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein] |
CTD |
PMID:32453893 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation |
ISO |
SB 203580 inhibits the reaction [S-allylcysteine results in increased phosphorylation of TP53 protein] [Diethylnitrosamine co-treated with S-allylcysteine] results in increased phosphorylation of TRP53 protein |
CTD |
PMID:31067004 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Upk2 |
uroplakin 2 |
multiple interactions |
ISO |
S-allylcysteine inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 mRNA]; S-allylcysteine inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 protein] |
CTD |
PMID:27234646 |
|
NCBI chr 8:48,772,906...48,774,898
Ensembl chr 8:48,772,906...48,774,898
|
|
|
G |
Msra |
methionine sulfoxide reductase A |
multiple interactions |
ISO |
S-methylcysteine promotes the reaction [MSRA protein results in decreased susceptibility to chloramine-T] |
CTD |
PMID:19085252 |
|
NCBI chr15:47,488,333...47,800,662
Ensembl chr15:47,488,894...47,800,024
|
|
G |
Pah |
phenylalanine hydroxylase |
increases oxidation |
ISO |
PAH protein results in increased oxidation of S-methylcysteine |
CTD |
PMID:19367645 |
|
NCBI chr 7:28,066,639...28,129,772
Ensembl chr 7:28,066,635...28,129,769
|
|